Literature DB >> 27812974

Structure and Regulation of AMPK.

Ravi G Kurumbail1, Matthew F Calabrese2.   

Abstract

AMP-activated protein kinase is a family of heterotrimeric serine/threonine protein kinases that come in twelve different flavors. They serve an essential function in all eukaryotes of conserving cellular energy levels. AMPK complexes are regulated by changes in cellular AMP:ATP or ADP:ATP ratios and by a number of neutraceuticals and some of the widely-used diabetes medications such as metformin and thiazolinonediones. Moreover, biochemical activities of AMPK are tightly regulated by phosphorylation or dephosphorylation by upstream kinases and phosphatases respectively. Efforts are underway in many pharmaceutical companies to discover direct AMPK activators for the treatment of cardiovascular and metabolic diseases such as diabetes, non-alcoholic steatohepatitis (NASH) and diabetic nephropathy. Many advances have been made in the AMPK structural biology arena over the last few years that are beginning to provide detailed molecular insights into the overall topology of these fascinating enzymes and how binding of small molecules elicit subtle conformational changes leading to their activation and protection from dephosphorylation. In the brief review below on AMPK structure and function, we have focused on the recent crystallographic results especially on specific molecular interactions of direct synthetic AMPK activators which lead to biased activation of a sub-family of AMPK isoforms.

Entities:  

Keywords:  AMPK; Allostery; Crystallography; Enzyme activators; X-ray

Mesh:

Substances:

Year:  2016        PMID: 27812974     DOI: 10.1007/978-3-319-43589-3_1

Source DB:  PubMed          Journal:  Exp Suppl        ISSN: 1664-431X


  10 in total

1.  Human Cytomegalovirus Induces the Expression of the AMPKa2 Subunit to Drive Glycolytic Activation and Support Productive Viral Infection.

Authors:  Diana M Dunn; Irene Rodriguez-Sanchez; Xenia Schafer; Joshua Munger
Journal:  J Virol       Date:  2020-12-02       Impact factor: 5.103

2.  AMP-activated protein kinase contributes to cisplatin-induced renal epithelial cell apoptosis and acute kidney injury.

Authors:  Xiaogao Jin; Changlong An; Baihai Jiao; Robert L Safirstein; Yanlin Wang
Journal:  Am J Physiol Renal Physiol       Date:  2020-10-26

3.  Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.

Authors:  Lixiao Che; Xingyuan Yang; Chunmin Ge; Salim S El-Amouri; Qi-En Wang; Dao Pan; Thomas J Herzog; Chunying Du
Journal:  PLoS One       Date:  2019-05-15       Impact factor: 3.240

4.  Screening Potential Diagnostic Biomarkers for Age-Related Sarcopenia in the Elderly Population by WGCNA and LASSO.

Authors:  Shangjin Lin; Ming Ling; Cong Chen; Xiaoxi Cai; Fengjian Yang; Yongqian Fan
Journal:  Biomed Res Int       Date:  2022-09-13       Impact factor: 3.246

5.  Development and Verification of a Combined Diagnostic Model for Sarcopenia with Random Forest and Artificial Neural Network.

Authors:  Shangjin Lin; Cong Chen; Xiaoxi Cai; Fengjian Yang; Yongqian Fan
Journal:  Comput Math Methods Med       Date:  2022-08-23       Impact factor: 2.809

6.  A Highly Sensitive Non-Radioactive Activity Assay for AMP-Activated Protein Kinase (AMPK).

Authors:  Yan Yan; Xin Gu; H Eric Xu; Karsten Melcher
Journal:  Methods Protoc       Date:  2017-10-13

7.  Antagonism between salicylate and the cAMP signal controls yeast cell survival and growth recovery from quiescence.

Authors:  Maurizio D Baroni; Sonia Colombo; Enzo Martegani
Journal:  Microb Cell       Date:  2018-03-26

Review 8.  Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease.

Authors:  Daniel W Curry; Bernardo Stutz; Zane B Andrews; John D Elsworth
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

9.  Ethoxysanguinarine, a Novel Direct Activator of AMP-Activated Protein Kinase, Induces Autophagy and Exhibits Therapeutic Potential in Breast Cancer Cells.

Authors:  Yuan Si; Jiu Wang; Xuewen Liu; Tong Zhou; Yuchen Xiang; Te Zhang; Xianhui Wang; Tingting Feng; Li Xu; Qingqing Yu; Huzi Zhao; Ying Liu
Journal:  Front Pharmacol       Date:  2020-01-08       Impact factor: 5.810

10.  Non-cytotoxic doses of shikonin inhibit lipopolysaccharide-induced TNF-α expression via activation of the AMP-activated protein kinase signaling pathway.

Authors:  Fang Zhang; Tao Pan; Xiaohui Wu; Xingchun Gao; Zhikui Li; Xinling Ren
Journal:  Exp Ther Med       Date:  2020-09-03       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.